ABVC Biopharma Net Worth
ABVC Biopharma Net Worth Breakdown | ABVC |
ABVC Biopharma Net Worth Analysis
ABVC Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ABVC Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ABVC Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ABVC Biopharma's net worth analysis. One common approach is to calculate ABVC Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ABVC Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ABVC Biopharma's net worth. This approach calculates the present value of ABVC Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ABVC Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ABVC Biopharma's net worth. This involves comparing ABVC Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ABVC Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if ABVC Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ABVC Biopharma's net worth research are outlined below:
| ABVC Biopharma is way too risky over 90 days horizon | |
| ABVC Biopharma appears to be risky and price may revert if volatility continues | |
| ABVC Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 509.59 K. Net Loss for the year was (5.26 M) with profit before overhead, payroll, taxes, and interest of 507.9 K. | |
| ABVC Biopharma currently holds about 2.99 M in cash with (1.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| ABVC Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: ABVC BioPharma Records 100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program |
ABVC Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ABVC Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ABVC Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
ABVC Biopharma Target Price Consensus
ABVC target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. ABVC Biopharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most ABVC analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand ABVC stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of ABVC Biopharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationABVC Biopharma Target Price Projection
ABVC Biopharma's current and average target prices are 3.35 and 2.02, respectively. The current price of ABVC Biopharma is the price at which ABVC Biopharma is currently trading. On the other hand, ABVC Biopharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On ABVC Biopharma Target Price
Know ABVC Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ABVC Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ABVC Biopharma backward and forwards among themselves. ABVC Biopharma's institutional investor refers to the entity that pools money to purchase ABVC Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Honkamp Krueger Financial Services Inc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-03-31 | 104.5 K | Xtx Topco Ltd | 2025-03-31 | 60.4 K | Vanguard Group Inc | 2025-03-31 | 46.9 K | Ubs Group Ag | 2025-03-31 | 29 K | Northern Trust Corp | 2025-03-31 | 19.1 K | State Street Corp | 2025-03-31 | 12.9 K | Two Sigma Securities, Llc | 2025-03-31 | 11.5 K | Tower Research Capital Llc | 2025-03-31 | 2.6 K | Sbi Securities Co Ltd | 2025-03-31 | 460 |
Follow ABVC Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 56.89 M.Market Cap |
|
Project ABVC Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (4.79) | (5.03) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (4.00) | (3.80) |
When accessing ABVC Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ABVC Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ABVC Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of ABVC Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ABVC Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ABVC Biopharma's management manipulating its earnings.
Evaluate ABVC Biopharma's management efficiency
ABVC Biopharma has return on total asset (ROA) of (0.1091) % which means that it has lost $0.1091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4242) %, meaning that it created substantial loss on money invested by shareholders. ABVC Biopharma's management efficiency ratios could be used to measure how well ABVC Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of July 19, 2025, Return On Tangible Assets is expected to decline to -0.68. In addition to that, Return On Capital Employed is expected to decline to -5.03. At present, ABVC Biopharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 1.4 M, whereas Total Assets are forecasted to decline to about 4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.06 | 0.06 | |
| Tangible Book Value Per Share | 0.06 | 0.06 | |
| Enterprise Value Over EBITDA | (2.19) | (2.30) | |
| Price Book Value Ratio | 5.97 | 5.67 | |
| Enterprise Value Multiple | (2.19) | (2.30) | |
| Price Fair Value | 5.97 | 5.67 | |
| Enterprise Value | 10.9 M | 10.4 M |
The leadership approach at ABVC Biopharma's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 121.0867 | Revenue | Quarterly Revenue Growth (0.09) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ABVC Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ABVC Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ABVC Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ABVC Biopharma time-series forecasting models is one of many ABVC Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ABVC Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ABVC Biopharma Earnings Estimation Breakdown
The calculation of ABVC Biopharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ABVC Biopharma is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for ABVC Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
ABVC Biopharma Earnings Projection Consensus
Suppose the current estimates of ABVC Biopharma's value are higher than the current market price of the ABVC Biopharma stock. In this case, investors may conclude that ABVC Biopharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ABVC Biopharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 0 | 37.6% | -0.3918 | 0.0 | -0.19 |
ABVC Biopharma Earnings per Share Projection vs Actual
Actual Earning per Share of ABVC Biopharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering ABVC Biopharma predict the company's earnings will be in the future. The higher the earnings per share of ABVC Biopharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.ABVC Biopharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as ABVC Biopharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of ABVC Biopharma should always be considered in relation to other companies to make a more educated investment decision.ABVC Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact ABVC Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-04-15 | 2025-03-31 | 0 | 0.02 | 0.02 | 0 | ||
2023-11-15 | 2023-09-30 | -0.04 | -0.8181 | -0.7781 | 1945 | ||
2023-08-14 | 2023-06-30 | -0.06 | -0.6841 | -0.6241 | 1040 | ||
2023-05-15 | 2023-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2023-03-31 | 2022-12-31 | -0.15 | -0.15 | 0.0 | 0 | ||
2022-11-14 | 2022-09-30 | -0.12 | -0.11 | 0.01 | 8 | ||
2022-08-15 | 2022-06-30 | -0.12 | -0.06 | 0.06 | 50 | ||
2022-05-16 | 2022-03-31 | -0.2 | -0.2 | 0.0 | 0 | ||
2022-03-31 | 2021-12-31 | -0.04 | -0.31 | -0.27 | 675 | ||
2021-11-15 | 2021-09-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2021-08-12 | 2021-06-30 | -0.04 | -0.08 | -0.04 | 100 | ||
2021-03-16 | 2020-12-31 | -0.1 | -0.24 | -0.14 | 140 | ||
2017-06-30 | 2017-03-31 | 0 | -0.0183 | -0.0183 | 0 |
ABVC Biopharma Corporate Management
| TsungShann Jiang | Member Officer | Profile | |
| Leeds Chow | Chief Officer | Profile | |
| Howard MD | Pres CEO | Profile | |
| ChiHsin King | Chief Officer | Profile | |
| Uttam Patil | Chief Officer | Profile | |
| Eugene Jiang | Chairman Officer | Profile |
Already Invested in ABVC Biopharma?
The danger of trading ABVC Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ABVC Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ABVC Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ABVC Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.19) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.